Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation

Transfusion

Volumn 42, Issue 12, 2002, Pages 1567-1572

  Hutchinson, Kendra ^a,b,c   Kopko, Patricia M ^a,b,c   Muto, Kathryn N ^a,b,c   Tuscano, Joseph ^a,b,c   O'Donnell, Robert T ^a,b,c   Holland, Paul V ^a,b,c   Richman, Carol ^a,b,c   Paglieroni, Teresa G ^a,b,c   Wun, Theodore ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sacramento Medical Foundation Blood Center   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; AUTOTRANSPLANTATION; BLOOD TRANSFUSION; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNE DEFICIENCY; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STANDARD; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0036887284     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2002.00253.x     Document Type: Article

References (15)

1. 1 Linden JV, Pisciotto PT. Transfusion‐associated graft‐ versus‐host disease and blood irradiation. Transfus Med Rev 1992 ; 6: 116 ‐ 23.
2. 2 Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long‐term microchi‐ merism in severe trauma patients. Blood 1999 ; 93: 3127 ‐ 39.
3. 3 Petz LD, Calhoun L, Yam P, et al. Transfusion‐associated graft‐versus‐host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second‐degree relative, and a survey of predisposing factors. Transfusion 1993 ; 33: 742 ‐ 50.
4. 4 Wagner FF, Flegel WA. Transfusion‐associated graft‐versus‐host disease: risk due to homozygous HLA haplotypes. Transfusion 1995 ; 35: 284 ‐ 91.
5. 5 Holland PV. Transfusion‐associated graft‐versus‐host disease: Prevention using irradiated blood products. In: Garratty G (ed.). Current Concepts in Transfusion Therapy. Arlington (VA): American Association of Blood Banks, 1985;295‐315.
6. 6 Juji T, Nishimura M, Tadokoro K. Treatment of post transfusion Graft‐Versus‐Host Disease. Vox Sang 2000 ; 78: 277 ‐ 9.
7. 7 Fiebig E, Hirschkorn DF, Maino VC, Grass JA, Lin L, Busch MP. Assessment of donor T‐cell function in cellular blood components by the CD69 induction assay: effects of storage, gamma radiation, and photochemical treatment. Transfusion 2000 ; 40: 761 ‐ 70.
8. 8 Leitman SF, Holland PV. Irradiation of blood products: indications and guidelines. Transfusion 1985 ; 25: 293 ‐ 300.
9. 9 Gresens CJ, Paglieroni T, Moss CB, et al. T cells in fresh frozen plasma are viable and can respond to mitogen, superantigen and allogeneic monocytes (abstract). Transfusion 1999 ; 39: 99S.
10. 10 Denardo GL, Denardo SJ, Goldstein DS, et al. P Maximum tolerated dose, toxicity, and efficacy of 131, I‐LYM‐1 antibody for fractionated radioimmunotherapy for non‐Hodgkin's Lymphoma. J Clin Oncol 1998 ; 16: 3246 ‐ 56.
11. 11 Briz M, Cabrera R, Sanjuan I, et al. Diagnosis of transfusion‐associated graft‐versus‐host disease by polymerase chain reaction in fludarabine‐treated B‐chronic lymphocytic leukaemia. Br J Haematol 1995 ; 91: 409 ‐ 11.
12. 12 Maung ZT, Wood AC, Jackson GH, Turner GE, Appleton AL, Hamilton PJ. Transfusion‐associated graft‐versus‐host disease in fludarabine‐treated B‐chronic lymphocytic leukemia. Br J Haematol 1994 ; 88: 649 ‐ 52.
13. 13 Williamson LM, Wimperis JZ, Wood ME, Woodcock B. Fludarabine treatment and transfusion‐associated graft‐versus‐host disease. Lancet 1996 ; 348: 472 ‐ 3.
14. 14 Keating MJ, O'Brien S, Robertson LE, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Seminars Oncol 1993 ; 20 (Suppl): 13 ‐ 20.
15. 15 Wijermans PW, Gettis WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. European J Hematol 1993 ; 50: 292 ‐ 6.